Identification of survival-promoting OSIP108 peptide variants and their internalization in human cells by Verbandt, Sara et al.
Accepted Manuscript
Title: Identification of survival-promoting OSIP108 peptide
variants and their internalization in human cells
Author: Sara Verbandt So´nia Troeira Henriques Pieter
Spincemaille Peta J. Harvey Gursimran Chandhok Vanessa
Sauer Barbara De Coninck David Cassiman David J. Craik
Bruno P.A. Cammue Kaat De Cremer Karin Thevissen
PII: S0047-6374(16)30129-4
DOI: http://dx.doi.org/doi:10.1016/j.mad.2016.07.013
Reference: MAD 10879
To appear in: Mechanisms of Ageing and Development
Received date: 25-3-2016
Revised date: 30-6-2016
Accepted date: 30-7-2016
Please cite this article as: Verbandt, Sara, Henriques, So´nia Troeira, Spincemaille,
Pieter, Harvey, Peta J., Chandhok, Gursimran, Sauer, Vanessa, Coninck, Barbara
De, Cassiman, David, Craik, David J., Cammue, Bruno P.A., Cremer, Kaat De,
Thevissen, Karin, Identification of survival-promoting OSIP108 peptide variants
and their internalization in human cells.Mechanisms of Ageing and Development
http://dx.doi.org/10.1016/j.mad.2016.07.013
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
1 
 
Identification of survival-promoting OSIP108 peptide variants and 
their internalization in human cells  
 
Sara Verbandt1*, Sónia Troeira Henriques2*, Pieter Spincemaille1,3, Peta J. Harvey2, 
Gursimran Chandhok4, Vanessa Sauer4, Barbara De Coninck1,5, David Cassiman6, 
David J. Craik2, Bruno P.A. Cammue1,5#, Kaat De Cremer1,5§ and Karin Thevissen1§ 
 
1Centre of Microbial and Plant Genetics, CMPG, KU Leuven, Kasteelpark Arenberg 
20, box 2460, 3001 Leuven, Belgium 
2Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, 4072, 
Australia 
3Department of Laboratory Medicine, University Hospital Gasthuisberg, Herestraat 49, 
3000 Leuven, Belgium 
4Clinic for Transplantation Medicine, Münster University Hospital, Albert-Schweitzer-
Campus 1, Building A14, D-48149 Münster, Germany 
5Department of Plant Systems Biology, VIB, Technologiepark 927, 9052 Ghent, 
Belgium 
6Department of Hepatology and Metabolic Center, University Hospital Gasthuisberg, 
Herestraat 49, 3000 Leuven, Belgium. 
 
*both authors contributed equally 
 
2 
 
§Shared last author 
 
#Corresponding author. Mailing address: CMPG, Kasteelpark Arenberg 20, 3001 
Leuven, Belgium. Phone: +32 16329682. Fax: 32-16321966. E-mail: 
bruno.cammue@biw.kuleuven.be 
 
Running title: Structure-activity relationship study of OSIP108 
 
  
3 
 
Highlights 
 OSIP108 activity is improved by substitution of Val4, Leu5, Gln6 and Gly7 by 
charged residues or Pro 
 Substitutions of Cys3 and Arg9 most negatively affect OSIP108 activity 
 OSIP108[G7P] is the most active variant among 190 tested 
 OSIP108 and OSIP108[G7P] are highly flexible in solution 
 OSIP108 and OSIP108[G7P] internalize into HeLa cells 
 
Abstract 
The plant-derived decapeptide OSIP108 increases tolerance of yeast and human cells 
to apoptosis-inducing agents, such as copper and cisplatin. We performed a whole 
amino acid scan of OSIP108 and conducted structure-activity relationship studies on 
the induction of cisplatin tolerance (CT) in yeast. The use of cisplatin as apoptosis-
inducing trigger in this study should be considered as a tool to better understand the 
survival-promoting nature of OSIP108 and not for purposes related to anti-cancer 
treatment. We found that charged residues (Arg, His, Lys, Glu or Asp) or a Pro on 
positions 4-7 improved OSIP108 activity by 10% or more. The variant OSIP108[G7P] 
induced the most pronounced tolerance to toxic concentrations of copper and cisplatin 
in yeast and/or HepG2 cells. Both OSIP108 and OSIP108[G7P] were shown to 
internalize equally into HeLa cells, but at a higher rate than the inactive 
OSIP108[E10A], suggesting that the peptides can internalize into cells and that 
OSIP108 activity is dependent on subsequent intracellular interactions. In conclusion, 
our studies demonstrated that tolerance/survival-promoting properties of OSIP108 can 
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be significantly improved by single amino acid substitutions, and that these properties 
are dependent on (an) intracellular target(s), yet to be determined.  
 
Keywords: OSIP108, apoptosis-inducers, structure activity relationship study, 
survival, cellular internalization  
 
 
1. Introduction1 
Programmed cell death, or apoptosis, is essential for the function and development of 
multicellular organisms (Kerr et al., 1972). However, excessive apoptosis can lead to 
degenerative pathologies, such as Alzheimer’s, Parkinson’s, Huntington’s and 
Wilson’s disease (Butterfield, 2002; Jenner, 2003; Portera-Cailliau et al., 1995; Strand 
et al., 1998). As the life quality of patients that suffer from these disorders is largely 
impaired, elucidation of the detrimental mechanistic backgrounds that lead to these 
diseases and discovery of novel therapies are of utmost importance. Of relevance, anti-
apoptotic compounds have been proposed as potential therapeutics for treatment of 
these diseases (Friedlander, 2003; Mattson, 2000; Thompson, 1995).  
Owing to the highly conserved apoptotic pathways in eukaryotic cells, yeast 
(Saccharomyces cerevisiae) is an ideal eukaryotic model organism to study apoptosis,  
and information found in yeast can in many cases be directly translated to mammalian 
cells (Carmona-Gutierrez et al., 2010; Fröhlich et al., 2007). Hence, various yeast 
                                                          
1 Abbreviations in order of appearance: SAR, structure-activity relationship; CT, cisplatin tolerance; 
MTT, 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide; AUC, area under the curve; 
TB, Trypan blue; MCT-2, minimal peptide concentration required to increase CT of the culture by 2-
fold 
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models have been developed to study the above mentioned neurodegenerative diseases, 
mainly by overexpressing disease-inducing proteins that can form toxic aggregates and 
cause apoptosis, such as α-synuclein, amyloid-β and huntingtin, for studying 
Parkinson’s, Alzheimer’s and Huntington’s diseases (Bharadwaj et al., 2010; Flower et 
al., 2005; Meriin et al., 2002), respectively (reviewed in (Khurana and Lindquist, 2010; 
Winderickx et al., 2008)). In addition, a yeast model for the rare disease Wilson’s 
disease is also available. The latter is a condition characterized by excessive hepatic 
copper accumulation, resulting in apoptosis of hepatocytes, but also in 
neurodegeneration (Huster, 2010), and is caused by mutations in the copper transporter 
ATP7B (Ferenci, 2006; Forbes and Cox, 1998). As such, overexpression of ATP7B in 
a yeast mutant devoid of its orthologue Ccc2p, restored copper tolerance of the mutant 
(Hung et al., 1997).  
Yeast models can be used to study the molecular mechanisms leading to the described 
pathologies, but they can also aid in drug discovery through screening and identification 
of survival-promoting molecules and elucidation of their modes of action (Griffioen et 
al., 2006; Johnson et al., 2008; Verbandt et al., 2016; Winderickx et al., 2008). For 
instance, using a copper-toxicity yeast model for Wilson’s disease (Spincemaille et al., 
2014b), we have previously identified a potent anti-apoptotic peptide, OSIP108, 
derived from the plant Arabidopsis thaliana (De Coninck et al., 2013). This decapeptide 
increases the tolerance of yeast and human cells to apoptosis-inducing compounds such 
as copper and cisplatin (Spincemaille et al., 2014a, 2014b). Moreover, OSIP108 also 
decreases copper-induced hepatotoxicity in zebrafish larvae, showing the potential of 
this peptide to treat hepatotoxicity in Wilson’s disease (Spincemaille et al., 2014c). A 
preliminary structure-activity relationship (SAR) study of OSIP108 in the presence of 
cisplatin showed that the D-stereoisomer of OSIP108 and some cyclized variants have 
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an identical cisplatin tolerance (CT)-promoting activity on yeast cells compared to 
OSIP108 (Spincemaille et al., 2014a).  
In this study we aim to identify structural features important for survival-promoting 
properties of OSIP108 and to optimize its activity. To achieve this goal, we have 
performed a detailed SAR analysis of OSIP108 using a whole amino acid replacement 
scan, in which every single amino acid was replaced with the other 19 amino acids. The 
success of this approach was demonstrated in a previous study, using the same amino 
acid replacement scan, in which we could demonstrate that OSIP108’s antibiofilm 
activity was increased by introducing positively charged amino acids, whereas 
replacement of Arg9 by 17 out of 19 amino acids resulted in a reduction or even 
complete abolishment of this activity (Delattin et al., 2014b). In the present study, we 
used cisplatin as apoptosis-inducing trigger, as our high-throughput screening did not 
allow the use of copper. The latter is most relevant as causative agent of Wilson 
Disease, but the copper concentrations needed to induce yeast PCD cause cell 
aggregation under our bioscreen-based screening conditions (unpublished data). As 
cisplatin is used in the treatment of cancer, a peptide that promotes cisplatin tolerance 
can obviously never be considered for therapeutic applications in cancer settings. So, 
the cisplatin-based screening setup used here should only be regarded as a tool to better 
understand the survival-promoting nature of the OSIP108 peptide.  
Hence, in this study, we evaluated the CT-promoting activity of the OSIP108 variants 
and examined the potential of the best OSIP108 variant to increase copper-tolerance of 
yeast and human cells. In addition, we assessed potential internalization of OSIP108 
and some variants into human cervical cancer (HeLa) cells, and compared three-
dimensional structures of OSIP108 and its most active variant to further understand the 
SAR of this peptide regarding its survival-promoting properties.  
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2. Materials and methods 
2.1. Materials and microorganisms 
The Saccharomyces cerevisiae yeast strain (BY4741) was cultured in synthetic 
complete (SC) medium (0.77 g/L complete amino acid supplement mixture (CSM) (Bio 
101 Systems); 6.7 g/L yeast nitrogen base without amino acids (YNB); 20 g/L glucose). 
OSIP108 (MLCVLQGLRE) and the peptide variants (amino acid scan, double 
substitutions) were obtained from Pepscan (Lelystad, The Netherlands) with crude 
purity (< 70%). In addition, OSIP108 and OSIP108[G7P] were also obtained in 98% 
pure preparations (Pepscan). Of relevance, 98% pure OSIP108 and OSIP108[G7P] 
showed equal survival-promoting activity on yeast treated with CuSO4 compared to the 
crude peptide preparations (data not shown), justifying the use of crude peptide 
preparations throughout this manuscript. Cis-diamminedichloroplatinum (II) 
(Cisplatin), CuSO4.5H2O and CuCl2 were purchased from Sigma Aldrich (St. Louis, 
USA). Peptides (20 mM) and cisplatin (50 mM) were dissolved in dimethyl sulfoxide 
(DMSO). HeLa (human cervix epitheloid carcinoma cells) were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) (Gibco, Invitrogen) supplemented with 10% (v/v) 
of fetal bovine serum and 1% (w/v) penicillin/streptomycin. HepG2 cells (human 
hepatocellular carcinoma cells) (ATCC, Rockville, USA) were grown in RPMI media 
(Lonza) supplemented with 10 % fetal calf serum, 100 U/mL penicillin and 100 µg/mL 
streptomycin. Cell lines were cultured using standard cell culture conditions (37ºC, 5% 
CO2 in humidified atmosphere). 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT) was purchased from Sigma Aldrich. 
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2.2. Yeast CT assay 
An overnight yeast culture in SC was diluted to OD600 of 0.1 in fresh SC and treated 
with 2.5% DMSO (control) or 250 µM cisplatin with or without 100 µM of the peptides. 
Yeast growth was subsequently monitored by recording the OD600 with a bioscreen C 
MBR (Oy Growth Curves Ab, Ltd, Helsinki, Finland) every 15 minutes for 44 h. 
Experiments were performed at 30°C, while shaking continuously at medium 
amplitude. 
From the OD600 measurements, growth curves were plotted as OD600 values vs. time. 
To estimate the effect of a peptide-treatment on the growth of the cultures in the 
presence of a sublethal cisplatin dose (250 µM), we calculated a CT-score, which is the 
ratio of the area under the curve (AUC) of a peptide-treated culture to AUC of the 
untreated control (see supplementary figure S1 for CT-score calculation). To compare 
the potency of selected OSIP108 variants, dose response curves containing CT-scores 
vs. peptide concentration (12.5 µM- 100 µM) were plotted. MCT-2 values, i.e. the 
minimum concentration of the peptide necessary to increase the CT-score of a cisplatin 
treated culture by 2-fold, were determined for each of the OSIP108 variants. A 
graphical representation of the MCT-2 value is provided in supplementary figure S2. 
2.3. Yeast copper survival assay 
Yeast survival in presence of 1.75 mM CuSO4 upon treatment with either control (2% 
DMSO) or peptide (100 µM) was evaluated as before (Spincemaille et al., 2014b). 
2.4. HepG2 copper survival assay 
Viability of HepG2 cells in presence of 0.75 mM CuCl2 treated with either peptide (5 
µM- 100 µM) or control (1% DMSO) was assessed as previously described 
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(Spincemaille et al., 2014b). Briefly, HepG2 cells were seeded in a 96-well plate and 
incubated with control (1% DMSO) or peptide (5 µM-100 µM). Following 16 h 
preincubation, cells were incubated in new culture medium containing 0.75 mM CuCl2 
upon treatment with control or peptide. Cell viability was determined after 48 h by MTT 
staining and calculated as a percentage of untreated cells. 
2.5. HeLa copper survival assay 
HeLa cells were seeded in a 96-well plate at 104 cells/well and incubated with control 
(1% DMSO) or peptide (5 µM- 50 µM). Following 16 h preincubation, cells were 
incubated in new culture medium containing 0.4 mM CuCl2 upon treatment with control 
or peptide. Cell viability was determined after 24 h by MTT staining and calculated as 
a percentage of untreated cells. 
2.6. NMR analysis 
OSIP108 or OSIP108[G7P] (~1 mg) were dissolved in 550 L of 10% D2O/90% H2O 
and the pH adjusted to 3.0 for NMR experiments. Spectra were recorded at 298 K on a 
Bruker Avance-500 or an Avance-600 spectrometer. 2D NMR experiments included 
TOCSY (total correlation spectroscopy, mixing time of 80 ms) and ROESY (rotating 
frame nuclear Overhauser effect spectroscopy, spin lock of 200 ms). Chemical shifts 
were referenced to internal 2,2-dimethyl-2-silapentane-5-sulfonate (DSS).  
2.7. Internalization of OSIP and of its variants into HeLa cells 
OSIP108 and its variants were labeled with Alexa Fluor® 488 sulfodichlorophenol 
ester (Life technologies) through an amide bond (Torcato et al., 2013). Briefly, peptide 
(0.5 mg) solubilized in sodium bicarbonate buffer (100 mM, pH 8, 90 L) was 
incubated with dye (0.5 mg) solubilized in DMSO (10 L), with N,N-
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diisopropylethylamine (DIPEA; 1 L) and with the reducing agent tris(2-
carboxyethyl)phosphine (TCEP; 1 L of 20 mM stock) and incubated for 3 h at room 
temperature. Labeled peptide was separated from unlabeled peptide by RP-HPLC. 
OSIP108, OSIP108[G7P] and OSIP108[E10A] were labeled at the N-terminal amine, 
whereas OSIP108[M1K], OSIP108[R9K] and OSIP108[E10K] were labeled through 
the side chain amine of the Lys residue. Each peptide had a single label and was purified 
to >95% as checked by LC-MS. Peptide stock solutions were prepared in DMSO and 
the peptide concentration determined following the absorbance of Alexa Fluor® 488 at 
495 nm (495 = 71,000 M
-1.cm-1).  
HeLa cells were seeded in 24-well plates (105 cells per well) and following attachment 
overnight, internalization of fluorescently-labeled peptides was monitored by flow 
cytometry as described before (Huang et al., 2015; Torcato et al., 2013). Briefly, HeLa 
cells were incubated with labeled OSIP108 or OSIP108 variants (2 – 16 µM) for 1 h at 
37ºC in fresh medium without serum (to avoid peptide degradation). Fluorescently-
labeled TAT, a gold standard cell-penetrating peptide, and TAT-G, a non-penetrating 
analogue (D’Souza et al., 2014) were included as controls. Final DMSO background 
was kept below 8% (v/v) for all peptide concentrations tested; the potential effect of 
DMSO in the internalization was examined by comparing the internalization of TAT in 
the absence/presence of different percentages of DMSO. Cells were washed with cold 
phosphate buffer saline (PBS) to remove non-internalized peptide, harvested from the 
plate by trypsinization, centrifuged at 500 g at 4ºC, washed and re-suspended in cold 
PBS. Fluorescence emission (excitation at 488 nm and emission at 530 nm with a band 
pass of 30 nm) of treated cells (10.000 cells per sample) was monitored by flow 
cytometry (BD FACSCantoTM II) before and after addition of trypan blue (TB, 160 
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g/mL). DMSO did not affect the overall uptake of TAT or TAT-G in the conditions 
tested (up to 8% (v/v) of DMSO). 
2.8. Statistical analysis 
Values are represented as mean with standard error of the mean (SEM). The data were 
analysed using GraphPad Prism 6.0. P value < 0.05 was considered to be statistically 
significant. Prior to all statistical analysis, normality was tested using Shapiro-Wilk 
normality test (α = 0.05).  
3. Results 
3.1. SAR study of OSIP108 on yeast in the presence of cisplatin 
The apoptosis-inducing effect of cisplatin on the model yeast S. cerevisiae was 
quantified by scoring the cisplatin tolerance (CT) of a treated yeast culture as detailed 
in the Materials and Methods section. Treatment of yeast with 100 µM OSIP108 in the 
absence of cisplatin did not affect the growth (CT-score = 1) (data not shown), whereas 
treatment with 250 µM cisplatin reduced the growth by 90% (CT-score = 0.10 ± 0.03). 
Yeast cultures treated with 250 µM cisplatin and 100 µM OSIP108 showed a CT-score 
of 0.55 ± 0.04. Thus, the addition of 100 µM OSIP108 increased growth of a 250 µM 
cisplatin-treated culture by 5.5-fold.  
The effect of the 190 OSIP108 variants on yeast growth in the presence of cisplatin was 
tested and compared to that of OSIP108 and a heat map was constructed (Fig. 1), in 
which all amino acid-substituted OSIP108 variants are ranked relative to average CT-
score of OSIP108 for each individual amino acid. From this heat map, we can conclude 
that CT-promoting activity can be most improved (up to 30%) by replacing the amino 
acids on position 4 – 7. Out of 19 possible amino acid substitutions Val4 can be 
improved by 13 amino acid substitutions, Leu5 by 15, Gln6 by 10 and Gly7 by six, 
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respectively. A different view of these data is obtained by visualizing the amino acid 
replacement scan in a second heat map in which the amino acids are colour-coded based 
on their main characteristics (supplementary figure S3). In general, replacing the amino 
acids on positions 4-6 with positively (Lys, Arg or His) or negatively (Asp or Glu) 
charged amino acids or with Pro results in improved CT-promoting activity (except for 
introduction of His on position 6, Asp on position 4 and Glu on position 5 which affect 
CT-score by less than 10%). Also substitution of Gly7 by Pro and Asp results in 
improved CT-promoting activity. Additionally, introduction of positively charged 
amino acids on other positions (Lys on position 2, 7 and 8; and Arg on position 10) 
results in improved CT-promoting activity, while introduction of Lys on position 3 and 
His on position 8 negatively affects CT-promoting activity. In contrast, substitution of 
Cys3 by nine amino acids, Leu8 by six amino acids or Arg9 by eight out of the 19 
amino acids leads to a reduction (of at least 10%) of the average CT-score compared to 
native OSIP108, showing the importance of Cys3, Leu8 and Arg9 (Fig. 1). Other 
positions (Met1, Leu2 and Glu10) are less prone to affection of the CT-score. 
Interestingly, introduction of aromatic residues rarely results in improved CT-
promoting activity (only substitution of Leu2 by Tyr) and often results in reduced CT-
promoting activity (e.g. substitution of Cys3, Gly7, Leu8, Arg9 and Glu10 by Phe) 
(supplementary figure S3).  
3.2. OSIP108[G7P] is characterized by improved CT-promoting activity 
To further optimize the amino acid sequence of OSIP108 for maximal activity, we 
selected 18 OSIP108 variants with improved CT-promoting activity (Fig. 1), being 
L2G, L2K, L2Y, V4H, V4K, V4S, L5A, L5H, L5S, Q6E, Q6K, Q6P, G7D, G7K, G7P, 
L8K, L8M and E10R, and performed dose response curves (data not shown). (For the 
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sake of simplicity OSIP108 variants are referred to by the substitution, e.g., “G7P” 
instead of OSIP108[G7P]). These variants were selected based on two criteria: (i) being 
one of the three best variants conferring CT for each position; and (ii) increase of at 
least 10% in average CT-score (Fig. 1). We calculated the MCT-2 (minimal peptide 
concentration required to increase average CT-score by 2-fold) from the dose-response 
curves and results are shown in Table 1. The MCT-2 value of OSIP108 is 44.5 ± 3.4 
µM. 
Based on MCT-2 values, the best substitutions for each position are L2G, V4H, L5S, 
Q6P, G7P, L8K and E10R. The most promising single substituted OSIP108 variant was 
G7P with MCT-2 of 9.2 ± 1.4 µM (Table 1). To assess whether we could further 
increase the activity of the G7P variant, we combined the above best substitutions with 
G7P into double substituted variants, resulting in L2G/G7P, V4H/G7P, L5S/G7P, 
Q6P/G7P, L8K/G7P, E10R/G7P and tested their CT-promoting activity at different 
concentrations (Fig. 2). We compared sample MCT-2 values using one-way ANOVA 
followed by a Tukey-multiple comparison test (α = 0.05). Interestingly, we found that 
no further improvements in CT-promoting activity of G7P could be obtained based on 
SAR of OSIP108 (Table 1). In fact, a combination of the improved variant G7P with 
E10R (i.e., G7P/E10R) resulted in a significant reduction of the CT-promoting activity 
compared to that of the single G7P substitution (P value = 0.00036); the MCT-2 value 
of G7P/E10R was equal to that of OSIP108 (P value = 1) (Table 1).  
In conclusion, we showed that G7P is characterized by the most improved CT-
promoting activity of all tested variants, and that on average a 4.8-fold lower 
concentration of G7P, as compared to OSIP108, is required to obtain a similar CT-
improvement of the yeast culture.  
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3.3. G7P shows improved survival-promoting activity on yeast  
To assess whether G7P can also increase tolerance of yeast to another apoptosis-
inducer, being copper, we assessed survival of yeast cells treated with a toxic CuSO4 
dose (1.75 mM) in the presence of OSIP108 or G7P. This toxic copper dose was 
selected based on survival determination of yeast cultures treated with a range of copper 
doses as this dose decreased survival of the yeast culture to approximately 30%. (data 
not shown). The colony forming units (CFUs) were counted and survival percentages 
were calculated in comparison to the untreated control (no copper/no peptide). We 
found that the activity of G7P in this setup was significantly increased compared to that 
of OSIP108 (P value = 0.0124): treatment with G7P increased the survival of yeast cells 
in the presence of toxic copper by 1.7-fold (from 31% to 53%), but only 1.3-fold (from 
31% to 41%) when treated with the OSIP108 (Fig. 3A). 
3.4. G7P shows improved survival promoting activity on HepG2 cells 
To translate the yeast-based data to a higher eukaryotic cell model we assessed the 
effect of OSIP108 and G7P on viability of HepG2 cells (human hepatocellular 
carcinoma cells) treated with copper. The choice for copper-induced toxicity in HepG2 
cells is based on the direct correlation between copper-induced toxicity in hepatocytes 
and the human Wilson’s disease (Huster, 2010). We first treated HepG2 cells with 
different copper concentrations and selected 0.75 mM CuCl2 for further experiments, 
as this concentration reduced HepG2 viability by more than 50% (Fig. 3B). Treatment 
with OSIP108 and G7P increased survival compared to the copper-treated control at all 
peptide doses (5 µM– 50 µM) (supplementary figure S4; P value < 0.05). Note that 
treatment of untreated HepG2 cells (without copper) with OSIP108 did not affect 
survival. At a peptide dose of 20 µM, we measured significant improvement in survival 
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by treatment with G7P compared to treatment with OSIP108 (Fig. 3B; P value = 0.013). 
Whereas viability of HepG2 cells was approx. 40% after challenge with 0.75 mM 
CuCl2, treatment with 20 µM OSIP108 or G7P increased viability to 56% and 66%, 
respectively (Fig. 3B). When comparing treatment of HepG2 cells with both peptides 
at higher peptide dose (50 µM), we observed no difference in survival of cell cultures 
after treatment with G7P compared to OSIP108 (both peptides increased viability up to 
almost 70%). Using lower peptide concentrations (5 µM and 10 µM), we measured a 
substantial, however not significant (α = 0.05), increase in survival by treatment with 
G7P compared to native OSIP108 (see supplementary figure S4). These results show 
improved survival-promoting activity of G7P as compared to OSIP108 on HepG2 cells 
in the presence of toxic copper doses.  
To gain further insight in the structure of OSIP108 and G7P, we performed NMR 
analysis of OSIP108 and of the improved variant G7P. The 1D 1H NMR spectrum of 
both these peptides showed poor dispersion in the amide region, indicative of limited 
secondary structure. Secondary chemical shift analysis (Fig. 4) also indicated that 
neither peptide adopted any secondary structure and that both OSIP108 and G7P were 
highly flexible and ‘random coil’ in nature. Replacing the Gly at position 7 by a Pro did 
not increase the peptide’s rigidity nor induce any local structure.  
3.5. OSIP108 and G7P are internalized into HeLa cells, whereas inactive 
E10A is not 
To obtain more insight in the activity of OSIP108, we assessed potential cell 
internalization of OSIP108. To this end, we used a N-terminally labelled OSIP108 with 
Alexa fluor®488 and assessed its internalization into HeLa cells, the most common 
model cell used to conduct internalization assays. The gold standard cell-penetrating 
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peptide TAT was included as a positive control, and its derivative TAT-G (in which 
positively-charged residues are replaced with Gly) was used to evaluate non-specific 
cellular internalization. Trypan blue (TB), a membrane-impermeable dye, was added to 
quench the fluorescence of cells with compromised membranes and/or the fraction of 
membrane-bound peptide (Torcato et al., 2013). The mean fluorescence emission signal 
of peptide-treated cells obtained after addition of TB is proportional to the amount of 
peptide internalized into cells, whereas the percentage of fluorescent cells gives 
information on the fraction of viable cells which have peptide internalized.  
Using flow cytometry we found that OSIP108 is internalized into HeLa cells in non-
permeabilising conditions: after one hour incubation all cells (>98%) became 
fluorescent (Fig. 5A, left panel), and the mean fluorescence signal was significantly 
higher than in cells treated with the negative control TAT-G (P value = 0.029, Fig. 5B). 
To examine whether the CT-promoting activity of OSIP108 correlates with the ability 
to internalize into cells, we monitored the internalization rate of two OSIP108 variants 
E10A and G7P, which respectively are inactive and active to promote CT in yeast as 
compared to OSIP108 (Fig. 5C). The inactive E10A showed a significantly decreased 
internalization rate (P value = 0.007 at 16 M), Fig. 5C), whereas the more active G7P 
showed identical internalization efficiency rate compared to that of OSIP108 (P value 
> 0.99999 at 16 M). Internalization of the peptides suggests (an) intracellular 
interaction(s) to promote survival. However, when measuring activity of OSIP108 and 
G7P on HeLa cells, we observed a significant reduction in cell survival of peptide-
treated cells in the absence of copper (supplementary figure S5). This reduction was 
even more pronounced for G7P compared to native OSIP108 (P value = 0.0051 at 20 
M). In the presence of 0.4 mM copper, the reduced survival was only substantial for 
G7P-treated HeLa cells (supplementary figure S5). 
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4. Discussion 
OSIP108 is a plant-derived decapeptide with anti-apoptotic properties (Spincemaille et 
al., 2014b). Its therapeutic potential was previously demonstrated as it can increase 
survival of several eukaryotic cell models for Wilson’s disease, such as a copper-treated 
Chinese Hamster Ovary (CHO) cell line expressing either ATP7B or ATP7BH1069Q, or a 
copper-treated U87 glioblastoma cell line (Spincemaille et al., 2014c). We previously 
also translated these findings to a zebrafish larvae model for Wilson’s disease. Injection 
of OSIP108 in zebrafish larvae reduced the copper-induced aberrancies in liver 
morphology and hepatotoxicity showing the potential of this peptide and potentially 
more active variants as lead peptides for the development of a novel peptide-based 
therapy for Wilson’s disease.  
The main aim of the present study was to identify important amino acids that are 
relevant for the tolerance-/survival-promoting activity of OSIP108. Thus, we have 
performed a detailed SAR analysis of OSIP108, using a whole amino acid replacement 
scan. We found that the CT-promoting activity of OSIP108 can be most improved (up 
to 30%) by replacing the amino acids on position 4 – 7 (Val4, Leu5, Gln6 and Gly7, 
respectively). In general, replacing these amino acids with positively (Lys, Arg or His) 
or negatively (Asp or Glu) charged amino acids or with Pro, results in improved CT-
promoting activity. Additionally, introduction of positively charged amino acids on 
other positions (Lys on position 2, 7 and 8; and Arg on position 10) also results in 
improved CT-promoting activity. Potentially, the introduction of charged residues 
enhances the solubility of the peptide, improves its cellular uptake and/or interaction 
with its target. The presence of a Pro residue might affect the secondary structure of the 
peptide, however, this was not confirmed for the G7P variant which was as flexible in 
solution as the native OSIP108. Interestingly, introduction of aromatic residues at 
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different positions results in reduced CT-promoting activity. Introduction of aromatic 
residues has been shown to impose steric blocking and as such might hinder interactions 
of the peptide with (a) possible interaction partner(s) (Bai et al., 1993). Substitutions of 
Cys3 and Arg9 most negatively affect the CT-promoting activity. These findings are in 
agreement with our previous studies in which a cyclic OSIP108 variant with a 
disulphide bond between Cys3 and a C-terminally added Cys (Cys11) showed reduced 
CT-promoting activity (Spincemaille et al., 2014a), and with the study of (Delattin et 
al., 2014b), as explained below.  
We previously showed that OSIP108 can also inhibit formation of Candida albicans 
biofilms (Delattin et al., 2014c). C. albicans is the predominant human fungal pathogen 
and accounts for 35% of invasive fungal infections (Lewis et al., 2013). C. albicans 
cells can also grow as a surface-attached biofilm, e.g., on catheters and heart valves, 
thereby causing recurrent systemic infections (Cuéllar-Cruz et al., 2012; Mayer et al., 
2013), which are in general resistant to most antimycotics (De Cremer et al., 2015; 
Delattin et al., 2014a). In the search for novel antibiofilm molecules, we previously 
identified OSIP108 as a new antibiofilm peptide (Delattin et al., 2014c). To get more 
insight into important amino acids that are linked to OSIP108’s antibiofilm activity, we 
also performed a SAR using the same amino acid replacement scan (Delattin et al., 
2014b). In line with the observations in our current study, the antibiofilm activity of 
OSIP108 could be increased by introducing positively charged amino acids whereas 
replacement of Arg9 by 17 out of 19 amino acids resulted in a reduction or even 
complete abolishment of this activity. However, it seems that some amino acid 
substitutions have a different effect on OSIP108’s activity in both setups. For example, 
substitution of Leu5 by 15 out of 19 leads to improved CT-promoting activity whereas 
12 of these amino acid improvements lead to a decreased antibiofilm activity of 
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OSIP108. To better understand the apparent differences in amino acid requirements for 
optimal activity of OSIP108 in both setups, it will be essential to determine the 
corresponding OSIP108 target(s). 
Moreover, the present study indicates that site-specific amino acid substitutions can 
significantly improve the CT- and survival-promoting activity of OSIP108. Studying 
OSIP108 variants with single and double substitutions allowed us to select the single 
substitution OSIP108 variant G7P as the best OSIP108 variant with regard to CT- and 
survival-promoting potential. OSIP108 G7P is characterized by a 4.8-fold decrease in 
MCT-2 on yeast cells treated with 250 µM cisplatin as compared to OSIP108. Note that 
G7P-based double substitution variants (like G7P/E10R) displayed even reduced CT-
promoting potential, showing that combination of single substitutions that positively 
affect the CT-promoting activity (e.g. G7P and E10R) does not necessarily translate 
into a further activity improvement. A full SAR analysis of G7P should be performed 
to either confirm the superiority of this variant or to further improve its activity. 
NMR analysis showed that both OSIP108 and its G7P variant are highly flexible in 
solution. As such, the improved activity of G7P cannot be attributed to alterations in its 
structure. This improved activity of G7P was confirmed in yeast and human HepG2 
cultures treated with copper, pointing to the generally improved tolerance-promoting 
activity of this peptide variant. In human HepG2 cells, both OSIP108 and G7P were 
able to increase copper-affected cell survival from 40% to almost 70%, a maximal 
threshold that was reached at lower concentrations for G7P, illustrating its superiority 
over native OSIP108 in this cell line.  
Our future research is aimed at discovering the target of OSIP108 and its active variants, 
which could be both intracellular or extracellular. To discriminate between those two 
options, we investigated whether native OSIP108, the improved G7P variant and an 
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inactive variant (E10A) could be internalized into human HeLa cells. Interestingly, we 
could demonstrate that OSIP108 and G7P are internalized in HeLa cells, in contrast to 
the E10A variant. Note that similar internalization of peptides in both HepG2 and HeLa 
cells has been reported (Fang et al., 2013; Richard et al., 2005).  These data suggest that 
the absence of E10A activity is correlated with its compromised uptake. At this 
moment, it is unclear whether the impeded internalization of E10A is due to a specific 
change in the C-terminal sequence or the difference in overall charge (caused by the 
substitution of a Glu residue). The latter is unlikely, since several substitutions of this 
position (e.g by Gly, Ile, Val and Leu) affecting overall charge in the same way as E10A 
were still active. Internalization of OSIP108 and G7P suggests that activity is conferred 
via intracellular interactions, leading to a survival benefit in HepG2 cells but reduced 
survival of HeLa cells. This inconsistency might be explained by differences within the 
reaction of both cell types to the stressor (copper), or absence/inactivity of targets 
necessary for the OSIP108 rescuing mechanisms. Indeed, HeLa cells are reported to be 
sensitive to the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) while 
HepG2 cells are TRAIL-resistant cancer cells, potentially explaining the observed 
difference in this apoptosis context (Shi et al., 2005).  
It is currently not clear how uptake of small peptides like OSIP108 could be mediated 
in yeast. Yeast possesses transporters for di-/tripeptides (encoded by PTR2 and DAL5) 
(Cai et al., 2007; Homann et al., 2005) and for tetra-/pentapeptides (encoded by OPT1 
and OPT2) (Aouida et al., 2009; Bourbouloux et al., 2000). However, a transport system 
for decapeptides has not yet been found in S. cerevisiae, but assessing the mode of 
uptake of OSIP108 might add information on such systems.  
In conclusion, we found improved activity of G7P as compared to OSIP108 in both 
yeast and human HepG2 cells. Both peptides are equally flexible in solution and are as 
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efficiently internalized in HeLa cells. Based on all these findings, we will focus our 
future research on the identification of the intracellular OSIP108 target. As the 
internalization efficiency of OSIP108 and G7P were found to be the same, and they are 
both unstructured, the improved activity of G7P is likely to relate to its improved 
interaction with (an) intracellular target(s), yet to be identified.   
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FIGURES 
 
Figure 1. SAR study of OSIP108. Cisplatin tolerance (CT)-promoting activity of yeast 
treated with 100 µM of each OSIP108 variants in the presence of 250 µM cisplatin was 
determined. Variants are coloured based on the CT-score relative to treatment with 
OSIP108 in the same conditions. The OSIP108 sequence is shown in black. OSIP108 
variants are ranked from the highest decrease (top) to the highest increase (bottom) in 
CT-score. Values are averages of three independent experiments, each with two 
technical replicates.  
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Figure 2. Dose response curves of OSIP108[G7P] double substituted variants. 
Dose response curves of cisplatin tolerance (CT)-promoting activity of different doses 
of OSIP108 (black line) and G7P variants (coloured lines). Yeast cultures were treated 
with peptide (12.5 µM- 100 µM) in presence of 250 µM cisplatin and incubated in the 
Bioscreen C plate reader. CT-scores are averages of at least three biologically 
independent experiments performed in duplicate. The dashed line at CT-score of 0.2 
represents a two-fold increase in CT-score compared to the cisplatin-treated control, 
based on which MCT-2 values were calculated.  
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Figure 3. G7P increases survival of yeast and HepG2 cells in the presence of toxic 
copper. (A) Yeast cells were mock-treated (control 2% DMSO) or treated with 100 µM 
of either peptide (OSIP108 or the G7P variant) in the presence of CuSO4 (1.75 mM). 
Survival (%) was calculated by determining CFUs of the copper-treated control as 
compared to the untreated control. (B) HepG2 cells were mock-treated (control 1% 
DMSO) or treated with 20 µM of either peptide (OSIP108 or the G7P variant) in 
presence of 0.75 mM CuCl2. Subsequently, cell viability was determined by MTT 
staining and expressed relative to control-treated cells in absence of copper. Yeast 
experiments were performed in quadruplicate in four biological repeats, whereas 
HepG2 experiments were performed in triplicate in three biological repeats. (*p<0.05; 
***p<0.001; ANOVA test using Bonferroni corrections). 
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Figure 4. Secondary shift analysis of OSIP108 and OSIP108[G7P]. The amino acid 
sequence is displayed. White bars represent OSIP108; grey bars represent the G7P 
variant.  
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Figure 5. Internalization of OSIP108 and its variants into HeLa cells. Cells were 
incubated with fluorescently-labelled peptides for 1 h at 37ºC and the internalization 
was monitored by measuring the fluorescence emission intensity of Alexa Fluor®488 
(excitation at 488 nm and emission at 530/30 nm) using flow cytometry. Fluorescence 
was measured before and after addition of the non-cell permeable quencher trypan blue 
(TB; 160 g/mL); 10.000 cells were screened per sample. (A) Left panel, dotplots of 
the side scatter as a function of the fluorescence emission intensity of cells treated with 
4 M OSIP108 vs untreated cells (blank) obtained after addition of TB. Both axis are 
in log scale and the gate was drawn to exclude non-fluorescent cells. Virtually all the 
cells treated with 4 M OSIP108 become fluorescent. Right panel, fluorescence 
emission intensity histograms of cells treated with varying concentrations of OSIP108. 
(B) Mean fluorescence emission intensity of cells treated with 4 M of TAT, TAT-G 
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or OSIP108, before and after addition of TB. Fluorescence intensity was normalized 
for the average signal obtained with TAT after addition of TB. Data are represented as 
mean  SEM of eight replicates. The statistical analysis was performed by one-way 
ANOVA by comparison with TAT-G after addition of TB (*p < 0.05). (C) Mean 
fluorescence emission intensity of cells treated with increasing concentrations of 
OSIP108, or of its variants E10A and G7P (4 µM- 16 µM). Fluorescence intensity was 
normalized for the average signal obtained with 4 µM TAT after addition of TB. Data 
are represented as mean  SEM of three replicates.   
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TABLES 
Table 1. Cisplatin tolerance (CT)-promoting activity of selected OSIP108 variants. 
OSIP108 variants with increased activity are further characterized by MCT-2, i.e. the 
minimum peptide concentration needed to increase CT by 2-fold compared to the 
cisplatin-treated control, and FC, i.e. fold change relative to OSIP108 (FC = MCT-2 
OSIP108/MCT-2 OSIP108 variant). NA = not applicable. MCT-2 values for all peptide 
variants were significantly different from the MCT-2 of OSIP108 (α < 0.05; one-way 
ANOVA test using Tukey post hoc analysis) except for the variants indicated with *. 
MCT-2 ± SEM are values of at least three biologically independent experiments with 
duplicate repeats.  
OSIP108 variant Sequence MCT-2 ± SEM (µM) FC P value 
OSIP108 MLCVLQGLRE 44.5 ± 3.4 NA NA 
L2G MGCVLQGLRE 21.2 ± 3.8 2.1 0.00023 
L2K MKCVLQGLRE 21.3 ± 1.8 2.1 0.03273 
L2Y MYCVLQGLRE 35.2 ± 1.7* 1.3 0.99982 
V4H MLCHLQGLRE 16.6 ± 1.7 2.7 0.00000 
V4K MLCKLQGLRE 27.1 ± 1.0* 1.6 0.39438 
V4S MLCSLQGLRE 21.8 ± 2.1 2.0 0.04320 
L5A MLCVAQGLRE 16.1 ± 0.5 2.8 0.01806 
L5H MLCVHQGLRE 16.7 ± 1.7 2.7 0.00192 
L5S MLCVSQGLRE 10.9 ± 0.8 4.1 0.00000 
Q6E MLCVLEGLRE 37.4 ± 3.9* 1.2 0.99998 
Q6K MLCVLKGLRE 25.9 ± 2.5* 1.7 0.11600 
Q6P MLCVLPGLRE 24.4 ± 5.3* 1.8 0.05235 
G7D MLCVLQDLRE 21.4 ± 2.8 2.1 0.03417 
G7K MLCVLQKLRE 21.5 ± 2.8 2.1 0.03634 
G7P MLCVLQPLRE 9.2 ± 1.4 4.8 0.00000 
L8K MLCVLQGKRE 14.7 ± 1.7 3.0 0.00000 
L8M MLCVLQGMRE 14.9 ± 0.9 3.0 0.00980 
E10R MLCVLQGLRR 15.8 ± 3.7 1.8 0.00828 
L2G/G7P MGCVLQPLRE 9.3 ± 0.9 4.8 0.00001 
V4H/G7P MLCHLQPLRE 9.4 ± 1.0 4.8 0.00001 
L5S/G7P MLCVSQPLRE 13.9 ± 2.0 3.2 0.00026 
Q6P/G7P MLCVLPPLRE 14.6 ± 2.0 3.1 0.00042 
L8K/G7P MLCVLQPKRE 22.6 ± 4.3 2.0 0.06487 
E10R/G7P MLCVLQPLRR 41.7 ± 6.0* 1.1 1.00000 
 
